Interview: Paolo Casati – General Manager, Santen Italy
Paolo Casati, general manager for Santen’s new affiliate in Italy, discusses the company’s first full year in the country, its aims for contributing to the global group’s 2020 Vision by…
In the last decade, Santen has strengthened its presence in Europe and has become a major player in the field of ophthalmology.
Santen is one of the few international companies specialized mainly in ophthalmology. Currently, Santen operates with leading university research centers and key opinion leaders in Europe to better understand diseases and illnesses. Basically, the work will be used to facilitate the diagnosis and management of these conditions.
Santen is committed to protect and improve eyesight, especially eye disorders that require new approaches to treatment.
The company has established its presence in Italy in 2014, in order to reflect its renewed determination to be patient-centric and expand in Europe.
Contact
Piazza Sigmund Freud, 1
20154 Milano
ITALIA
Tel.: +39 02 6200191
Fax: +39 02 62001999
Web: santen.eu/it
Paolo Casati, general manager for Santen’s new affiliate in Italy, discusses the company’s first full year in the country, its aims for contributing to the global group’s 2020 Vision by…
While the Italian clinical research community works to an excellent standard of quality, and is relatively competitive in terms of costs, regulatory differences with the rest of Europe pose significant…
Gnosis is a fully vertically integrated biotech company specialized in the manufacturing and sales of fermentation raw materials and natural finished products used in the pharmaceutical, nutraceutical, cosmetic, veterinary, and…
Charles-Henri Bodin, General Manager of Pierre Fabre, explains how the recent agreement with Pfizer on Toviaz will enlarge their footprint in Italy and how partnerships will play an increasing role…
Raffaele Stefanelli discusses the challenges of the medtech industry in Italy, the contribution of the Italian research community to Boston Scientific globally, and innovative partnership models. Could you introduce yourself…
Samsung is focused on the total digital transformation of medical services. It offers solutions in mobile health, hospital digitalization, and integrated medical and healthcare devices. The head of the healthcare…
Ahead of the imminent acquisition of Baxalta by Shire, country managing director Italy Fabio Andreola shares his perspective on the rare-disease environment in Italy and how Baxalta will contribute to…
Maurizio Marchesini, CEO of Marchesini Group, discusses the challenges of competing in a very dynamic packaging machinery industry, where their business is differentiated through flexibility and integral service offerings. Further,…
Riccardo Palmisano, CEO of MolMed, discusses the latest developments for their late-stage clinical development products, and comments on the recent approval of Strimvelis, a gene therapy developed by GSK and…
Paolo Marcucci, President and CEO of Kedrion Biopharma, talks about the factors behind the company’s incredible growth and its commitment to doubling exports to the US. Furthermore, he talks about…
Shire Italy’s Francesco Scopesi discusses innovative medicine, rare diseases, growth drivers, global strategy, and the new trend of home care. Shire is today one of the leading biotechs delivering innovative…
Long renowned for dancing to a different tune, Italy’s eccentric, but more often than not, enlightened and high performance pharma, healthcare and life sciences community may at last be about…
Doppel has been selected as the nucleus for significant investments in the CDMO industry by PE firm Trilantic Capital Partners, according to recently hired CEO Giuseppe Cassisi, who shares the organization’s plans to…
See our Cookie Privacy Policy Here
